ES2522567T3 - Composición farmacéutica que comprende amlodipino y losartán - Google Patents

Composición farmacéutica que comprende amlodipino y losartán Download PDF

Info

Publication number
ES2522567T3
ES2522567T3 ES07851323.1T ES07851323T ES2522567T3 ES 2522567 T3 ES2522567 T3 ES 2522567T3 ES 07851323 T ES07851323 T ES 07851323T ES 2522567 T3 ES2522567 T3 ES 2522567T3
Authority
ES
Spain
Prior art keywords
amlodipine
pharmaceutically acceptable
losartan
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07851323.1T
Other languages
English (en)
Inventor
Jong Soo Woo
Hong Gi Yi
Moon Hyuk Chi
Kyeong Soo Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2522567(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Application granted granted Critical
Publication of ES2522567T3 publication Critical patent/ES2522567T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición para su uso en la prevención o el tratamiento de trastornos cardiovasculares que comprende amlodipino o una sal farmacéuticamente aceptable del mismo, losartán o una sal farmacéuticamente aceptable del mismo y excipientes farmaceuticamente aceptables, en la que el amlodipino o una sal farmaceuticamente aceptable del mismo y el losartán o una sal farmacauticamente aceptable del mismo estan separados fisicamente entre si, pudiendo obtenerse dicha composición mediante un metodo que comprende las etapas de granular amlodipino o una sal farmacéuticamente aceptable del mismo para obtener una parte de granulos de amlodipino, y mezclar la parte de granulos de amlodipino con una parte de mezcla que comprende losartán o una sal farmacéuticamente aceptable del mismo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES07851323.1T 2006-12-08 2007-12-07 Composición farmacéutica que comprende amlodipino y losartán Active ES2522567T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020060124552A KR101247583B1 (ko) 2006-12-08 2006-12-08 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
KR20060124552 2006-12-08
PCT/KR2007/006352 WO2008069612A1 (en) 2006-12-08 2007-12-07 Pharmaceutical composition comprising amlodipine and losartan

Publications (1)

Publication Number Publication Date
ES2522567T3 true ES2522567T3 (es) 2014-11-17

Family

ID=39492408

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07851323.1T Active ES2522567T3 (es) 2006-12-08 2007-12-07 Composición farmacéutica que comprende amlodipino y losartán

Country Status (19)

Country Link
US (1) US20100233261A1 (es)
EP (1) EP2037917B1 (es)
JP (1) JP4995912B2 (es)
KR (1) KR101247583B1 (es)
CN (1) CN101472587B (es)
AU (1) AU2007328630B2 (es)
BR (1) BRPI0713306A8 (es)
CA (1) CA2654054C (es)
EC (1) ECSP088980A (es)
ES (1) ES2522567T3 (es)
IL (1) IL195581A (es)
MX (1) MX2008016099A (es)
MY (1) MY144857A (es)
NO (1) NO20085302L (es)
NZ (1) NZ573223A (es)
RU (1) RU2401107C2 (es)
UA (1) UA92641C2 (es)
WO (1) WO2008069612A1 (es)
ZA (2) ZA200910116B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI503119B (zh) * 2009-01-23 2015-10-11 Hanmi Science Co Ltd 含有氨氯地平（ａｍｌｏｄｉｐｉｎｅ）及洛沙坦（ｌｏｓａｒｔａｎ）之固體藥學組成物及其製造方法
JP5658172B2 (ja) * 2009-01-23 2015-01-21 ハンミ・サイエンス・カンパニー・リミテッド アムロジピン及びロサルタンを含む固形薬剤学的組成物及びその製造方法
CN101849942B (zh) * 2009-04-02 2012-05-23 鲁南制药集团股份有限公司 治疗高血压的药物组合物
CN101849941B (zh) * 2009-04-02 2012-04-18 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物
NZ597317A (en) * 2009-06-30 2014-05-30 Sanofi Sa Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
JP2011136908A (ja) * 2009-12-25 2011-07-14 Kyowa Yakuhin Kogyo Kk アンギオテンシンｉｉ受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンｉｉ受容体拮抗剤の保存安定性向上方法
WO2012055941A1 (en) * 2010-10-27 2012-05-03 Krka,Tovarna Zdravil, D. D., Novo Mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
CN102335172B (zh) * 2011-07-20 2012-12-12 海南锦瑞制药股份有限公司 一种氨氯地平与氯沙坦钾药用组合物及其制备方法
KR101907881B1 (ko) * 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR20150078215A (ko) * 2013-12-30 2015-07-08 (주) 드림파마 에프로사탄 및 암로디핀을 포함하는 복합제제 및 이의 제조방법
KR102369607B1 (ko) * 2014-09-30 2022-03-03 한미약품 주식회사 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물
KR101914930B1 (ko) * 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
KR101750689B1 (ko) * 2015-09-15 2017-06-26 주식회사 종근당 약제학적 복합제제
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
CN110215455A (zh) * 2019-03-26 2019-09-10 山东省药学科学院 一种用于降血压的药物配方
CN112274490B (zh) * 2020-11-19 2022-11-22 四川尚锐生物医药有限公司 一种氨氯地平氯沙坦钾复方组合物的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216881T1 (de) * 1996-06-24 2002-05-15 Merck & Co Inc Zusammensetzung auf basis von enalapril und losartan
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US20040137062A1 (en) * 2001-05-25 2004-07-15 Sham Chopra Chronotherapy tablet and methods related thereto
JP2007528349A (ja) * 2003-01-27 2007-10-11 ハンミ ファーム． シーオー．， エルティーディー． 高い安定性を有する無定形アムロジピンカムシレート、その製造方法及びこれを含む経口投与用組成物
RS20050590A (sr) * 2003-01-31 2007-09-21 Sankyo Company Limited, Lek za profilaksu i tretman arterioskleroze i hipertenzije
AR043395A1 (es) * 2003-02-28 2005-07-27 Recordati Ireland Ltd Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050209288A1 (en) * 2004-01-12 2005-09-22 Grogan Donna R Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
RS53141B (sr) * 2004-11-05 2014-06-30 Boehringer Ingelheim International Gmbh Dvoslojna tableta koja sadrži telmisartan i amlodipin
TWI388345B (zh) * 2005-06-27 2013-03-11 Sankyo Co 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Also Published As

Publication number Publication date
CA2654054A1 (en) 2008-06-12
JP2009544752A (ja) 2009-12-17
IL195581A0 (en) 2009-09-01
HK1131916A1 (en) 2010-02-12
WO2008069612A1 (en) 2008-06-12
EP2037917B1 (en) 2014-10-08
EP2037917A4 (en) 2010-08-04
RU2401107C2 (ru) 2010-10-10
KR20080052852A (ko) 2008-06-12
BRPI0713306A2 (pt) 2012-04-17
ZA200810116B (en) 2010-07-28
ECSP088980A (es) 2009-02-27
KR101247583B1 (ko) 2013-03-26
NO20085302L (no) 2009-06-17
ZA200910116B (en) 2010-07-28
AU2007328630A1 (en) 2008-06-12
CN101472587A (zh) 2009-07-01
IL195581A (en) 2015-08-31
CA2654054C (en) 2013-01-08
AU2007328630B2 (en) 2010-03-11
MY144857A (en) 2011-11-30
EP2037917A1 (en) 2009-03-25
US20100233261A1 (en) 2010-09-16
BRPI0713306A8 (pt) 2016-06-07
JP4995912B2 (ja) 2012-08-08
CN101472587B (zh) 2013-11-20
RU2008150477A (ru) 2010-06-27
NZ573223A (en) 2012-07-27
UA92641C2 (ru) 2010-11-25
MX2008016099A (es) 2009-01-19

Similar Documents

Publication Publication Date Title
AR065096A1 (es) Preparacion solida
CL2007002526A1 (es) Un medicamento que comprende, separado o juntos: a) una sal de glicopirronio; b) un agonista del adreno-receptor beta-2 seleccionado de salmeterol y formoterol; y c) un corticosteroide; kit farmaceutico; y uso en el tratamiento de una enfermedad infl
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
AR054114A1 (es) Composiciones farmaceuticas que comprenden imatinib y un retardador de la liberacion
NO20091501L (no) Farmasoytiske sammensetninger
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
ATE458486T1 (de) Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung
CL2007003684A1 (es) Compuestos derivados de indol con un anillo unido en las posiciones 5 y 6; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion viral.
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
CL2007002866A1 (es) Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
ZA200802873B (en) Solid orally administerable pharmaceutical dosage forms with rapid active principle release
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
NO20081016L (no) Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser
CR9723A (es) Nueva forma cristalina de un derivado de piridazino[4,5-b] indol
CL2008001104A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-b]piridin-carboxamidas y [1,2,3]triazolo[4,5-d]pirimidin-carboxamidas, inhibidores de mgl y faah; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de delolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metaloico, dispipidemia, entre otros.
ECSP088980A (es) Composicion farmacéutica que comprende amlodipina y losartán
CL2006002831A1 (es) Compuestos derivados de sulfonamida: proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por el receptor de glucocorticoides.
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
CL2007000680A1 (es) Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc.
CL2015001615A1 (es) Una composicion farmaceutica que comprende vortioxetina y donepezilo junto con un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de disfuncion cognitiva, demencia en la enfermedad de alzheimer, disfuncion cognitiva asociada a la depresion y a la esquizofrenia, entre otras enfermedades.
CL2016000788A1 (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016)
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CL2007002511A1 (es) Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune.